<DOC>
	<DOCNO>NCT00542269</DOCNO>
	<brief_summary>This proof concept study design evaluate efficacy safety combination therapy aliskiren ramipril add-on amlodipine treatment patient essential hypertension metabolic syndrome respond adequately amlodipine monotherapy .</brief_summary>
	<brief_title>Efficacy Safety Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine Aliskiren/Amlodipine Patients With Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Outpatients 1875 year age . Male female patient eligible . Patients diagnosis hypertension : Newly diagnose patient patient treated hypertension within 4 week prior Visit 1 must mean sit systolic blood pressure ( MSSBP ) &gt; 150 mmHg &lt; 180 mmHg Visit 1 . Patients treat antihypertensive monotherapy must MSSBP ≥ 140 mmHg &lt; 180 mmHg Visit 1 . Patients take amlodipine monotherapy MSSBP &gt; 140 mmHg &lt; 180 mmHg visit 1 . All patient must MSSBP ≥ 140 mmHg &lt; 180 mmHg Visit 3 , end amlodipine runin period . Metabolic syndrome . Patients eligible able participate study , consent purpose nature investigation clearly explain ( write inform consent form ) . Severe hypertension ( office cuff MSDBP ≥ 115 mmHg and/or MSSBP ≥ 180 mmHg ) . History evidence secondary form hypertension . History hypertensive encephalopathy cerebrovascular accident , transient ischemic cerebral attack ( TIA ) , myocardial infarction , coronary bypass surgery , percutaneous coronary intervention ( PCI ) . Serum sodium &lt; 135 mmol/L Visit 1 confirm repeat sample . Serum potassium &lt; 3.5 mmol/L ≥ 5.3 mmol/L Visit 1 , confirm repeat sample . Type 1 diabetes mellitus . Type 2 diabetes oral hypoglycaemic therapy change ( dose change medication change ) previous 3 month . Pregnant nursing ( lactate ) woman . Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Metabolic Syndrome</keyword>
	<keyword>Dual combination therapy</keyword>
	<keyword>Triple combination therapy</keyword>
	<keyword>Aliskiren</keyword>
	<keyword>Direct Renin inhibitor</keyword>
</DOC>